Early Phase 1 Pancreatic Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to sign a consent form before any study procedures begin
• People who are 18 years of age or older at the time of signing consent
• People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard medical scale called the ECOG scale (scores 0–2, meaning fully active to capable of limited self-care) (confirm with trial site)
• People who have been diagnosed with a locally advanced or metastatic form of pancreatic cancer called adenocarcinoma
• People who may have received prior treatment for their pancreatic cancer, or who have not yet had any treatment — however, at least 14 days must have passed since finishing the most recent treatment before starting the study drug
• People who have at least one tumour that can be safely biopsied (a small tissue sample taken for testing) according to their treating hospital's standards
• People who agree to have at least 2 biopsies — one before treatment and one after (in some cases, a previously stored tissue sample may be used instead of the pre-treatment biopsy, at the doctor's discretion)
• People whose blood counts and organ function meet the following levels (confirm with trial site):
  • Red blood cell level (haemoglobin) of at least 7.5 g/dL
  • White blood cell level (neutrophils) at or above a specified minimum
  • Platelet count at or above a specified minimum
  • Kidney function above a certain level, based on a standard calculation
  • Liver enzyme levels within an acceptable range (a higher range is allowed if cancer has spread to the liver)
• People who are able to become pregnant and agree to use effective contraception or abstain from sexual intercourse from the first dose until 6 months after the last dose, and who have a negative pregnancy test at screening and within 7 days of starting treatment
• People who can produce sperm and agree to use effective contraception or abstain from sexual intercourse from the first dose until 6 months after the last dose

Who may not be able to join:

• People who are currently receiving other cancer treatments not permitted by this study, such as chemotherapy, immunotherapy, certain hormonal therapies, radiation therapy (except for pain relief), biological therapies, or other experimental treatments
• People who have received any anti-cancer therapy within the 2 weeks before enrolling in the study
• People who have previously been treated with a type of drug called a MYC inhibitor
• People with a known serious allergy to the study drug (OMO-103) or any of its ingredients, or who have had allergic reactions to similar types of compounds
• People who have had major surgery within 6 weeks before enrolling
• People with certain serious or uncontrolled heart conditions, including heart failure with symptoms, unstable chest pain, irregular heart rhythm, or a heart attack within the past 3 months
• People with a history of a psychiatric condition that could make it difficult to follow the study requirements or give informed consent
• People who are pregnant, breastfeeding, or planning to become pregnant or father a child during the trial period and up to 6 months after the last dose
• People whom the study doctor believes should not participate, such as those unlikely to be able to follow the study's procedures and requirements

Important: Always verify eligibility with the trial site directly before applying.